Board of Pharmacy rule relating to pharmacist recovery networks
Summary
SB 361 concerns a Board of Pharmacy rule relating to pharmacist recovery networks. Based on the bill caption, the measure appears to address regulatory standards or procedures governing programs that support pharmacists dealing with substance use, impairment, or other recovery-related issues, likely through the state Board of Pharmacy’s rulemaking authority. Because the bill text was not available in the provided materials, the precise statutory changes cannot be identified from the record here.
The bill was referred to the Senate Judiciary Committee on January 15, 2026, indicating it was being reviewed for legal and regulatory implications rather than having completed the legislative process. No committee transcript, amendment record, or vote history was provided, so the available context does not show any substantive changes made to the proposal or any final policy outcome.
Impact
If enacted, SB 361 would likely affect the West Virginia Board of Pharmacy’s authority to adopt or revise rules concerning pharmacist recovery networks and could influence how pharmacists are referred to, monitored by, or participate in recovery-support programs. The bill may also affect pharmacists, pharmacies, professional monitoring programs, and any entities involved in impairment intervention or rehabilitation. Without the bill text, the specific statutes or regulatory provisions amended cannot be confirmed.
Sentiment
The available record does not include committee debate or recorded votes, so there is no direct evidence of support or opposition from the legislative process. The bill’s referral to Judiciary suggests it was being examined for legal sufficiency and policy effects, but the provided materials do not show whether the measure was controversial or broadly supported. Overall, the sentiment cannot be reliably determined from the available information.
Contention
No specific points of contention are documented in the provided materials. In general, legislation involving pharmacist recovery networks can raise questions about confidentiality, disciplinary consequences, eligibility for participation, public safety, and the balance between professional rehabilitation and regulatory enforcement. However, none of those issues are attributed to any particular legislator, committee member, or stakeholder in the record supplied here.